Of the sixteen items that make up a Comprehensive Product Information Summary, the fourth is the product information section, commonly called product information (DI). The development history tells the backstory; the features and clinical results present the heart of the efficacy claim. Right after these comes this section. The order carries meaning. Just behind the narrative and the appeal, a window is inserted that gathers the approved facts themselves, pulling the reader back to the official record. This is the spot in the material that sits closest to the (electronic) package insert.

01Why place an "approved-information window" inside the material

The foreword makes it explicit: the basis for proper-use information is the (electronic) package insert, and Product Information Summaries merely supplement it. That single word, supplement, does a lot of work. The Product Information Summary sits below the (electronic) package insert; the approved content is the original. So a material can never step even one character beyond the scope of approval.

Yet if a healthcare professional, holding the material, had to track down a separate (electronic) package insert every time to learn the correct usage, the duty to "convey accurately" would not be met. So a single window summarizing the approved information is placed inside the summary. That is the DI section. The material is not a substitute for the (electronic) package insert, but it builds one reliable bridge to it. Without this bridge, the attractive wording of the features section could end up walking off on its own.

In other words, this section is also a device for cooling the heat of the pitch. By lining up the immovable facts — regulatory category, indications, dosage and administration, warnings, contraindications — right after the pages that sell efficacy, it draws the reader's understanding back inside the frame of approval.

02What "follow the latest (electronic) package insert" really means

An (electronic) package insert is not a static document. As safety knowledge accumulates, warnings are added, contraindications widen, and adverse-reaction entries are updated. A drug's safety information moves most dramatically after launch. Merely copying the (electronic) package insert as it stood the moment the material was printed can leave it outdated six months later.

So this section must be grounded in the latest version of the (electronic) package insert available at the time of preparation. A convenient phrase from an old version, or recycling a draft used before, is fatal here. The freshness of the safety information is what decides the quality of this section.

03Detailed rules: how to place the revision notice at the top

State "stay fully alert to revisions" in a prominent position

At the top of the relevant page of this section, place a sentence to the effect that one should stay fully alert to revisions of precautions information, including warnings and contraindications, in a form that will not be overlooked. It is not mere boilerplate. The material is fixed in time as a printed object, but the (electronic) package insert moves — this notice exists to warn the reader of that time gap in advance.

"The wording in this material may differ from the (electronic) package insert you are reading right now. The final basis is the (electronic) package insert." That, in essence, is what the opening sentence says. It is a declaration that lowers the material's own authority by one notch and yields to the original.

State the preparation or revision date

As of when does the (electronic) package insert that was followed stand? Stating the preparation or revision date answers that. Without a date, the reader cannot judge whether the material's information is new or old. Only with the date can one verify that "this material is based on the (electronic) package insert of the such-and-such version."

This resonates with the very last of the sixteen items, Item 16, "Date of Preparation or Revision." Again and again the Creation Guide forces a record of "as of when." Keeping the version on record, preserving a state in which it can later be verified and recalled — the accumulation of that quiet discipline is what supports the material's trustworthiness.

04A design that blocks "true but misleading"

One implication of the foreword is the point that the duty not to lie and the duty not to mislead are separate. Even if every entry is factual, it is a violation if the manner of presentation lets the reader form a mistaken image. The DI section is no exception.

For instance, if the revision-notice sentence is pushed into a corner in type far smaller than the body text, on paper it counts as "stated." In substance, it goes unread. The Creation Guide's instruction to make it "prominent" exists to block this kind of formal box-ticking. Not only what is written, but how it is shown, falls within the reach of the rule.

05Consistency — relations with other items and norms

The DI section does not stand alone. It must be consistent with the cluster of items that handle the same approved facts from other angles: the warnings and contraindications on the cover (Item 1), the safety entries in clinical results (Item 5), the approval dates in related information (Item 13), and the principal references (Item 14). A mismatch in which only the window is old, or only the cover is new, erodes the trust of the whole.

The foreword further states that the Creation Guide covers basic matters, not everything, and that matters outside its provisions still fall under the Pharmaceuticals and Medical Devices Act, the Standards for Fair Advertising, the sales-information-provision activity guideline, and the JPMA Code. Even when you hit a question about DI wording that the Creation Guide does not spell out, "not written down" does not mean "free." You return to the higher norms and to the original-respecting spirit of supplementation to decide.